PATENT CLAIM ANALYSIS

Application Number: 15963535
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-08
Patent Classification: ["514", "210200"]

Abstract:
The present invention provides compounds of formula (I) which inhibit the activity of PI 3-kinase gamma isoform, which are useful for the treatment of diseases mediated by the activation of PI 3-kinase gamma isoform.

Claim (Index 2):
The compound according to  claim 1  of formula (Ia) wherein R 1  is independently selected from H, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, C 1-4  haloalkoxy, C 1-4  hydroxyalkyl and C 3-7  cycloalkyl; R 2  is selected from H, halogen, CF 3  and methyl; R 3  is selected from (i) C 1-4  alkyl which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkyl, oxo, CN, \u2014(C 0-3  alkyl)-NR 3a R 3b , C 3-7  cycloalkyl and C 3-7  heterocyclyl, and wherein the C 3-7  cycloalkyl or C 3-7  heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (ii) C 1-4  alkoxy which is unsubstituted or substituted with 1 or more substituents, particularly 1 to 3 substituents, independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  haloalkyl, C 1-4  alkoxy, C 1-4  alkyl, oxo, CN, \u2014(C 0-3  alkyl)-NR 3a R 3b , C 3-7  cycloalkyl and C 3-7  heterocyclyl, and wherein the C 3-7  cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (iii) \u2014C 3-7  cycloalkyl or \u2014O\u2014C 3-7  cycloalkyl wherein the C 3-7  cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (iv) a \u2014(C 0-3  alkyl)-C 3-7  cycloalkyl or \u2014O\u2014(C 0-3  alkyl)-C 3-7  cycloalkyl wherein the C 3-7  cycloalkyl is spiro fused to a second C 3-7  cycloalkyl or C 3-7  heterocyclyl by one single carbon atom, and wherein the C 3-7  cycloalkyl or C 3-7  heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (v) a \u2014(C 0-3  alkyl)-C 3-7  heterocyclyl or \u2014O\u2014(C 0-3  alkyl)-C 3-7  heterocyclyl, and wherein said C 3-7  heterocyclyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (vi) a \u2014(C 0-3  alkyl)-C 3-7  heterocyclyl or \u2014(O\u2014C 0-3  alkyl)-C 3-7  heterocyclyl, and wherein said C 3-7  heterocyclyl is spiro fused to a second C 3-7  heterocyclyl or a C 3-7  cycloalkyl by one single carbon atom, and wherein the C 3-7  heterocyclyl or C 3-7  cycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; (vii) H; R 4  is selected from H and C 1-4  alkyl; or R 3  and R 4  together with the nitrogen atom to which they are attached form a C 3-7  heterocyclyl, which C 3-7  heterocyclyl is optionally spiro fused to a second C 3-7  heterocyclyl or a C 3-7  cycloalkyl by one single carbon atom, and which C 3-7  heterocyclyl and C 3-7  cycloalkyl are unsubstituted or substituted with 1 to 3 substituents independently selected from hydroxy, C 1-4  hydroxyalkyl, halogen, C 1-4  alkyl, C 1-4  alkoxy, C 1-4  haloalkyl, oxo and \u2014(C 0-3  alkyl)-NR 3a R 3b ; R 3a  and R 3b  are independently selected from H, C 1-4  alkyl and C 1-4  haloalkyl; Y is selected from the group consisting of\n thiazolyl, \n thiadiazolyl, \n isothiazolyl, \n pyrazolyl, \n pyridyl, \n pyrimidinyl, \n triazolyl, \n imidazolyl, \n oxadiazolyl, \n isoxazolyl, \n oxazolyl, \n pyrrolyl, \n thienyl, and \n furanyl; \n each of which is unsubstituted or substituted with 1 to 3 substituents independently selected from C 1-4  alkyl, C 1-4  haloalkyl, C 1-4 alkoxyC 1-4 alkyl, C 1-4 hydroxyalkyl, C 1-4  alkoxy, C 1-4  haloalkoxy, halogen, C 1-4  hydroxyalkyl, \u2014(C 0-3  alkyl)-NR\u2032R\u2033, \u2014(C 0-3  alkyl)-C 3-7  cycloalkyl and \u2014(C 0-3  alkyl)-C 3-7  heterocyclyl, \u2014(C\u2550O)\u2014C 3-7  heterocyclyl, \u2014(C\u2550O)\u2014NR\u2032R\u2033, \u2014(C 0-3  alkyl)-phenyl and \u2014(C 0-3  alkyl)-5-6-membered heteroaryl; R\u2032 and R\u2033 are independently selected from H and C 1-4  alkyl; or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.35714
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15303879', '15303868', '15303890', '12765904', '15736450']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8464824396593515
- 35 USC 102 Novelty (BERT): 0.598508682414355
- Combined Prediction Score: 0.8216850639348519
- Mean Citation Score: 436.623092
- Max Citation Score: 539.0702
- Similarity Product: 471.1959439450383

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test